We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alzheimer’s Patients May Need Dosing Modifications to Meds Prescribed for Other Conditions
News

Alzheimer’s Patients May Need Dosing Modifications to Meds Prescribed for Other Conditions

Alzheimer’s Patients May Need Dosing Modifications to Meds Prescribed for Other Conditions
News

Alzheimer’s Patients May Need Dosing Modifications to Meds Prescribed for Other Conditions

Credit: Ivan Cujic, Pexels
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alzheimer’s Patients May Need Dosing Modifications to Meds Prescribed for Other Conditions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Patients with Alzheimer’s disease (AD) are often prescribed drugs for other conditions — including diabetes or high blood pressure — at the same doses as those without dementia. That practice might need to be reexamined in the wake of new mouse studies reported in ACS’ Molecular Pharmaceutics. The findings suggest that AD could alter absorption of medications from the digestive tract, so dosages might need to be adjusted for these patients.

Because AD is primarily considered a disease of the nervous system, scientists have mostly focused on its impact on drug uptake across the blood-brain barrier (BBB). Their research revealed that the quantity and function of proteins that transport drugs through the BBB are altered in people with AD. Less attention has been given to other biological barriers, such as the intestine’s lining, through which oral drugs pass into the bloodstream. The few small studies published on this subject, however, suggest that this absorption process may be disrupted in AD. Joseph A. Nicolazzo and colleagues wanted to know if these changes could occur with drugs commonly prescribed to AD patients.

Using mice that serve as a model for AD, the team measured absorption of compounds that move from the small intestine to the bloodstream through three different mechanisms. For example, blood plasma levels of diazepam, which diffuses passively through intestinal cells to reach the bloodstream, were similar in AD mice compared with control mice. But AD mice had less valsartan and digoxin in their plasma than controls. Passage of these drugs through intestinal cells is controlled by transporters that could be disrupted by AD, according to the team’s prior research. These drugs may also pass through gaps between intestinal cells, and tissue samples indicated that these gaps might be more restrictive in AD mice. If these findings translate to people with AD, the researchers recommend revisiting dosing regimens for certain drugs to ensure their plasma concentrations remain in the appropriate range.

Reference: Jin, et al. (2020) Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer’s Disease. Mol. Pharmaceutics. DOI:  https://doi.org/10.1021/acs.molpharmaceut.9b01227 

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement